Literature DB >> 17525162

Intranuclear protein transduction through a nucleoside salvage pathway.

James E Hansen1, Chung-Ming Tse, Grace Chan, Emil R Heinze, Robert N Nishimura, Richard H Weisbart.   

Abstract

Regulation of gene expression by intranuclear transduction of macromolecules such as transcription factors is an alternative to gene therapy for the treatment of numerous diseases. The identification of an effective intranuclear delivery vehicle and pathway for the transport of therapeutic macromolecules across plasma and nuclear membranes, however, has posed a significant challenge. The anti-DNA antibody fragment 3E10 Fv has received attention as a novel molecular delivery vehicle due to its penetration into living cells with specific nuclear localization, absence of toxicity, and successful delivery of therapeutic cargo proteins in vitro and in vivo. Elucidation of the pathway that allows 3E10 Fv to cross cell membranes is critical to the development of new molecular therapies. Here we show that 3E10 Fv penetrates cells through a nucleoside salvage transporter. 3E10 Fv is unable to penetrate into cells deficient in the equilibrative nucleoside transporter ENT2, and reconstitution of ENT2 into ENT2-deficient cells restores 3E10 Fv transport into cell nuclei. Our results represent the first demonstration of protein transport through a nucleoside salvage pathway. We expect that our finding will facilitate a variety of methods of gene regulation in the treatment of human diseases, open up new avenues of research in nucleoside salvage pathways, and enhance our understanding of the pathophysiology of autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17525162     DOI: 10.1074/jbc.C700090200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.

Authors:  Haiqing Yi; Tao Sun; Dustin Armstrong; Scott Borneman; Chunyu Yang; Stephanie Austin; Priya S Kishnani; Baodong Sun
Journal:  J Mol Med (Berl)       Date:  2017-02-02       Impact factor: 4.599

2.  Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion.

Authors:  M Kathryn Brewer; Annette Uittenbogaard; Grant L Austin; Dyann M Segvich; Anna DePaoli-Roach; Peter J Roach; John J McCarthy; Zoe R Simmons; Jason A Brandon; Zhengqiu Zhou; Jill Zeller; Lyndsay E A Young; Ramon C Sun; James R Pauly; Nadine M Aziz; Bradley L Hodges; Tracy R McKnight; Dustin D Armstrong; Matthew S Gentry
Journal:  Cell Metab       Date:  2019-07-25       Impact factor: 27.287

3.  Central Nervous System Delivery and Biodistribution Analysis of an Antibody-Enzyme Fusion for the Treatment of Lafora Disease.

Authors:  Grant L Austin; Zoe R Simmons; Jack E Klier; Alberto Rondon; Brad L Hodges; Robert Shaffer; Nadine M Aziz; Tracy R McKnight; James R Pauly; Dustin D Armstrong; Craig W Vander Kooi; Matthew S Gentry
Journal:  Mol Pharm       Date:  2019-08-02       Impact factor: 4.939

Review 4.  Targeted heat shock protein 72 for pulmonary cytoprotection.

Authors:  Missag H Parseghian; Stephen T Hobson; Richard A Richieri
Journal:  Ann N Y Acad Sci       Date:  2016-05-06       Impact factor: 5.691

5.  Cardioprotective Effects of HSP72 Administration on Ischemia-Reperfusion Injury.

Authors:  Takashi Tanimoto; Missag H Parseghian; Takehiro Nakahara; Hideki Kawai; Navneet Narula; Dongbin Kim; Robert Nishimura; Richard H Weisbart; Grace Chan; Richard A Richieri; Nezam Haider; Farhan Chaudhry; Glenn T Reynolds; John Billimek; Francis G Blankenberg; Partho P Sengupta; Artiom D Petrov; Takashi Akasaka; H William Strauss; Jagat Narula
Journal:  J Am Coll Cardiol       Date:  2017-09-19       Impact factor: 24.094

6.  Tumor suppressor and T-regulatory functions of Foxp3 are mediated through separate signaling pathways.

Authors:  Emil Heinze; Grace Chan; Rachel Mory; Raz Khavari; Asif Alavi; Sue Y Chung; Robert N Nishimura; Richard H Weisbart
Journal:  Oncol Lett       Date:  2011-05-13       Impact factor: 2.967

7.  Recombinant Fv-Hsp70 protein mediates neuroprotection after focal cerebral ischemia in rats.

Authors:  Xinhua Zhan; Bradley P Ander; Isaac H Liao; James E Hansen; Chester Kim; Douglas Clements; Richard H Weisbart; Robert N Nishimura; Frank R Sharp
Journal:  Stroke       Date:  2010-01-14       Impact factor: 7.914

8.  Targeting cancer with a lupus autoantibody.

Authors:  James E Hansen; Grace Chan; Yanfeng Liu; Denise C Hegan; Shibani Dalal; Eloise Dray; Youngho Kwon; Yuanyuan Xu; Xiaohua Xu; Elizabeth Peterson-Roth; Erik Geiger; Yilun Liu; Joseph Gera; Joann B Sweasy; Patrick Sung; Sara Rockwell; Robert N Nishimura; Richard H Weisbart; Peter M Glazer
Journal:  Sci Transl Med       Date:  2012-10-24       Impact factor: 17.956

Review 9.  DNA-damaging autoantibodies and cancer: the lupus butterfly theory.

Authors:  Philip W Noble; Sasha Bernatsky; Ann E Clarke; David A Isenberg; Rosalind Ramsey-Goldman; James E Hansen
Journal:  Nat Rev Rheumatol       Date:  2016-03-24       Impact factor: 20.543

10.  Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy.

Authors:  Michael W Lawlor; Dustin Armstrong; Marissa G Viola; Jeffrey J Widrick; Hui Meng; Robert W Grange; Martin K Childers; Cynthia P Hsu; Michael O'Callaghan; Christopher R Pierson; Anna Buj-Bello; Alan H Beggs
Journal:  Hum Mol Genet       Date:  2013-01-09       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.